Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap1.46B
Enterprise Value1.37B
GLUE
(NASDAQ)Monte Rosa Therapeutics, Inc.
$18.65-- (--)
Loading... - Market loading
Monte Rosa Therapeutics (GLUE) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)11.81
Forward Price/Sales7.22
Price/Book (mrq)6.27
Price/Tangible Book (mrq)6.27
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue11.08
EV/Earnings-35.46
EV/EBITDA-29.87
EV/EBIT-25.27
EV/FCF-49.81
Stock Price
Current price, 52-week range, and moving averages
Current Price$18.65
1-Day Change6.09%
52-Week High$25.77
52-Week Low$3.51
52-Week Change374.47%
YTD Change21.82%
1-Year Change365.09%
50-Day MA$17.84
200-Day MA$14.09
Avg Volume (30 day)791.12K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding83.07M
Book Value per Share$2.81
Net Cash per Share$1.09
FCF per Share$-0.33
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$23.13
Target Upside/Downside24.02%
Analyst ConsensusBuy
Analyst Count4
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin96.62%
EBITDA Margin (ttm)-37.08%
EBIT Margin (ttm)-43.83%
Operating Margin (ttm)-43.83%
Pretax Margin (ttm)-32.12%
Profit Margin (ttm)-31.23%
FCF Margin (ttm)-22.23%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-16.57%
Return on Assets (ttm)-8.61%
Return on Invested Capital (ttm)-30.08%
Return on Capital Employed (ttm)-14.10%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue123.67M
Gross Profit119.49M
Operating Income-54.21M
Pretax Income-39.72M
Net Income-38.63M
EBITDA-45.85M
EBIT-54.21M
Diluted EPS$-0.53
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-22.80M
Capital Expenditures4.70M
Free Cash Flow-27.50M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth63.54%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)448.66M
Cash & Securities (mrq)129.88M
Net Cash (mrq)90.69M
Net Cash per Share$1.09
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)39.19M
Working Capital (mrq)328.97M
Total Equity (mrq)233.06M
Book Value per Share$2.81
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)6.12
Quick Ratio (mrq)6.12
Debt/Equity (mrq)0.17
Debt/EBITDA (ttm)2.39
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-2.64%
FCF Yield-1.88%
Buyback Yield-1.66%
Total Shareholder Yield-1.66%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score1.67
Piotroski F-Score6/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$5.51
Graham Upside/Downside-70.46%
Frequently Asked Questions About Monte Rosa Therapeutics Statistics
What are the key financial metrics for GLUE?
Monte Rosa Therapeutics, Inc. (GLUE) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is GLUE's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Monte Rosa Therapeutics is overvalued or undervalued.
How do I read GLUE's profitability ratios?
Monte Rosa Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do GLUE's debt ratios indicate?
The financial health section shows Monte Rosa Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is GLUE's dividend analysis?
The dividend section covers Monte Rosa Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.